Mevion Single Room Proton Therapy System Treats more than 520 Patients in Two Years

Two year data from Ackerman Cancer Center proves the advantages of Mevion’s compact design, efficient workflow, and novel direct beam technology

The MEVION S250 at Ackerman Cancer Center has treated 526 patients in its first two years. (Photo: Business Wire)

???pagination.previous??? ???pagination.next???

LITTLETON, Mass.--()--In a major milestone for the proton therapy industry, the MEVION S250 Proton Therapy System at Ackerman Cancer Center (ACC) in Jacksonville, Fla., has treated 526 patients with proton therapy just 24 months after first patient treatment. This is the highest number of proton therapy patients ever treated in two years in a single room, and exceeds the two-year patient volume of many larger three-, four- and five-room systems.

“The MEVION S250 system’s direct beam technology, efficient clinical workflow and high system availability, combined with the collaboration and established treatment protocols of existing proton centers have made this exciting milestone possible,” said Scot Ackerman, MD, medical director of Ackerman Cancer Center. “We are able to treat a diverse set of cancers with proton therapy including breast, head and neck, lung, prostate, and others. Patients have come to us from all across the United States, Canada, and Central America for treatment. And our team is proud to be able to partner with Mevion to provide accessible proton therapy to our patients.”

Soon after it opened on April 30, 2015, the MEVION S250 system at Ackerman Cancer Center achieved the fastest per-room patient ramp-up in the history of proton therapy. It now treats, on average, 40 proton therapy patients per day during a 12-hour shift. The high throughput is due to the MEVION S250 system’s efficient, linac-like workflow, low maintenance requirements, and industry-leading uptime, demonstrating that compact proton therapy can be a viable option for any size cancer center. Based on the success of its first Mevion unit, ACC plans to install a second system, a MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning technology.

“The fact that Mevion is helping ACC provide so many patients with the cancer care they need validates our mission of delivering the most advanced, accessible, and financially viable proton therapy system available today,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “526 patients in two years of clinical operation would be a huge achievement for a multi-room center, and ACC has now achieved that goal with a single room.”

Proton therapy provides targeted radiation treatment for many types of cancer, significantly reducing the dose of radiation to healthy tissue by as much as a factor of three, while still maintaining high conformance to the treatment target. The National Comprehensive Cancer Network (NCCN) recently updated its clinical practice guidelines to add proton therapy as an appropriate therapy in the management of several additional critical indications including esophageal carcinomas, head and neck, hepatobiliary and non-small-cell lung carcinomas.

Mevion invented the compact proton therapy system to help increase access to this valuable therapy. Mevion currently has more compact systems treating patients than any other proton therapy manufacturer, with 100% of Mevion clinical sites achieving 100% of their financial objectives in the first year.

About Mevion Medical Systems®

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in Europe, Japan and China. For more information, please visit www.mevion.com.

About the MEVION S250 Series™

The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers.

The MEVION S250 Series includes:

  • MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities
  • MEVION S250i Proton Therapy System™ with HYPERSCAN™ with Adaptive Aperture™, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed
  • MEVION S250mx™, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime

The MEVION S250i Proton Therapy System with HYPERSCAN with Adaptive Aperture has not been cleared by the US FDA for clinical use.

Contacts

Mevion Contact:
Tom Langford, 617-761-6775
tom.langford@fkhealth.com
High Resolution Images Available

Release Summary

The MEVION S250 Proton Therapy System at Ackerman Cancer Center (ACC) in Jacksonville, Fla., has treated 526 patients with proton therapy just 24 months after first patient treatment.

Contacts

Mevion Contact:
Tom Langford, 617-761-6775
tom.langford@fkhealth.com
High Resolution Images Available